tiprankstipranks
Trending News
More News >
CK Life Sciences International (Holdings), Inc. (HK:0775)
:0775
Advertisement

CK Life Sciences International (Holdings), Inc. (0775) AI Stock Analysis

Compare
3 Followers

Top Page

HK:0775

CK Life Sciences International (Holdings), Inc.

(0775)

Rating:62Neutral
Price Target:
HK$1.00
▲(0.00%Upside)
The overall stock score of 62 is primarily driven by the technical analysis, which shows positive momentum. Despite this, financial performance concerns, particularly the negative net income and high leverage, weigh on the score. Valuation challenges, including a negative P/E ratio and lack of a dividend yield, further impact the stock's attractiveness.

CK Life Sciences International (Holdings), Inc. (0775) vs. iShares MSCI Hong Kong ETF (EWH)

CK Life Sciences International (Holdings), Inc. Business Overview & Revenue Model

Company DescriptionCK Life Sciences International (Holdings), Inc. (0775) is a biotechnology company primarily engaged in the research and development, manufacturing, and commercialization of products focused on the nutraceutical and pharmaceutical sectors. The company operates through two main business segments: healthcare, which includes pharmaceuticals and nutraceuticals, and agriculture-related businesses. CK Life Sciences is committed to improving human health and wellness through its innovative solutions and sustainable practices.
How the Company Makes MoneyCK Life Sciences makes money through a diversified revenue model that includes the sale of pharmaceuticals, nutraceuticals, and other health-related products. The company generates revenue from the development and commercialization of proprietary and licensed pharmaceutical products targeting various therapeutic areas. Additionally, its nutraceuticals business, which includes dietary supplements and health products, contributes significantly to its revenue. CK Life Sciences also earns income from its agriculture-related businesses, involving the development and sale of environmentally friendly fertilizers and crop protection products. Strategic partnerships and collaborations with other companies in the biotechnology and healthcare sectors further enhance its revenue streams.

CK Life Sciences International (Holdings), Inc. Financial Statement Overview

Summary
CK Life Sciences is facing profitability challenges with a negative net income in 2024 despite stable revenue growth. Operational efficiency has improved, but high leverage and a declining equity ratio raise financial stability concerns. Positive operating and free cash flows suggest some operational strength, yet the cash flow decline indicates potential cash management issues.
Income Statement
65
Positive
The company has shown a modest revenue growth of 3.75% from 2023 to 2024. However, it reported a negative net income in 2024, resulting in a net profit margin of -2.29%, indicating profitability challenges. The gross profit margin remained stable at 30.64%, and the EBIT margin improved to 14.18%, suggesting operational efficiency improvements despite bottom-line issues.
Balance Sheet
60
Neutral
The debt-to-equity ratio increased to 1.74, indicating a higher leverage, which could pose financial risks. The equity ratio decreased to 32.53%, reflecting a lower proportion of equity financing in the asset structure. ROE turned negative due to the net loss, highlighting the strain on shareholder returns.
Cash Flow
70
Positive
Operating cash flow remained positive, although it decreased by 31.23% from the previous year. Free cash flow declined by 30.74%, suggesting reduced excess cash for reinvestment. The free cash flow to net income ratio is not meaningful due to the negative net income, but the company maintained a positive free cash flow.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue5.52B5.32B5.28B5.40B4.94B
Gross Profit1.69B1.64B1.63B1.63B1.41B
EBITDA337.27M624.75M469.51M449.14M353.62M
Net Income-126.55M17.25M131.96M162.80M125.23M
Balance Sheet
Total Assets10.79B11.25B11.27B11.73B11.98B
Cash, Cash Equivalents and Short-Term Investments571.21M676.16M704.13M902.47M971.71M
Total Debt6.10B5.93B5.95B6.21B6.19B
Total Liabilities7.28B7.06B7.11B7.23B7.26B
Stockholders Equity3.51B4.19B4.16B4.50B4.72B
Cash Flow
Free Cash Flow154.06M222.35M146.69M206.33M151.12M
Operating Cash Flow353.53M514.18M363.66M423.57M530.96M
Investing Cash Flow-96.64M-67.96M-22.12M-257.88M-457.31M
Financing Cash Flow-341.98M-477.95M-515.34M-220.08M168.74M

CK Life Sciences International (Holdings), Inc. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price1.00
Price Trends
50DMA
0.88
Positive
100DMA
0.79
Positive
200DMA
0.62
Positive
Market Momentum
MACD
0.03
Negative
RSI
53.15
Neutral
STOCH
58.97
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0775, the sentiment is Positive. The current price of 1 is above the 20-day moving average (MA) of 0.91, above the 50-day MA of 0.88, and above the 200-day MA of 0.62, indicating a bullish trend. The MACD of 0.03 indicates Negative momentum. The RSI at 53.15 is Neutral, neither overbought nor oversold. The STOCH value of 58.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:0775.

CK Life Sciences International (Holdings), Inc. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
66
Neutral
HK$10.10B275.734.16%34.39%
62
Neutral
HK$8.94B-3.29%3.76%-833.33%
56
Neutral
HK$10.18B-13.97%-97.81%-117.20%
54
Neutral
HK$7.86B324.142.28%-57.55%-87.49%
54
Neutral
HK$7.73B-8.04%66.72%33.68%
51
Neutral
$7.35B0.50-65.61%2.47%15.28%1.44%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:0775
CK Life Sciences International (Holdings), Inc.
0.93
0.60
181.82%
HK:2315
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
25.45
19.15
303.97%
HK:2142
HBM Holdings Ltd.
9.02
7.72
593.85%
HK:1672
Ascletis Pharma, Inc.
10.50
9.52
971.43%
HK:1477
Ocumension Therapeutics
9.42
2.76
41.44%

CK Life Sciences International (Holdings), Inc. Corporate Events

CK Life Sciences Issues Profit Warning Amid Increased R&D Investments
Jul 31, 2025

CK Life Sciences International (Holdings) Inc. has issued a profit warning, indicating an expected loss of approximately HK$150 million for the first half of 2025, compared to a HK$1 million profit in the same period in 2024. This shift from profit to loss is primarily due to the company’s strategic decision to increase investments in research and development, while the overall operations remained stable. The final financial results are still being finalized and will be disclosed in the interim results announcement on 12 August 2025.

CK Life Sciences Announces Upcoming Board Meeting for Interim Results
Jul 31, 2025

CK Life Sciences International (Holdings) Inc. has announced that its board of directors will meet on August 12, 2025, to approve the interim results for the first half of the year and consider the payment of an interim dividend. This meeting is significant as it will provide insights into the company’s financial health and potential returns for shareholders, impacting its market positioning and stakeholder interests.

CK Life Sciences Secures Strong Shareholder Support at AGM
May 22, 2025

CK Life Sciences International (Holdings) Inc. successfully conducted its Annual General Meeting on May 22, 2025, where all proposed resolutions were passed with overwhelming support. The resolutions included the approval of the audited financial statements for 2024, the election of directors, the appointment of auditors, and the granting of mandates to issue and buy back shares. This outcome reinforces the company’s governance structure and operational strategy, potentially strengthening its market position and shareholder confidence.

CK Life Sciences Enhances Governance with Updated Nomination Committee Terms
May 22, 2025

CK Life Sciences International (Holdings) Inc. has outlined the terms of reference for its Nomination Committee, which was established to ensure effective corporate governance in compliance with the Hong Kong Stock Exchange’s Listing Rules. The committee is responsible for reviewing the board’s structure and composition, identifying and recommending director candidates, assessing director independence, and supporting board performance evaluations. These measures are designed to align the board’s capabilities with the company’s strategic goals and enhance shareholder value.

CK Life Sciences Strengthens Governance with New Audit Committee Terms
May 22, 2025

CK Life Sciences International (Holdings) Inc. has outlined the terms of reference for its Audit Committee, which plays a crucial role in overseeing the company’s financial reporting, risk management, and internal control systems. The Audit Committee is composed of non-executive directors, with a majority being independent, and is tasked with ensuring compliance with corporate governance standards. This announcement underscores the company’s commitment to maintaining robust governance practices, which is vital for stakeholder confidence and the company’s operational integrity.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 02, 2025